Previous 10 | Next 10 |
Immunocore Reports Second Quarter 2022 Financial Results and Provides Business Update KIMMTRAK® ( tebentafusp ) now approved in over 30 countries with commercial launches underway in U.S. and Germany, and paid access in France Net KIMMTRAK / tebentafusp ...
Immunocore to Report Second Quarter 2022 Earnings and Host Call on August 10, 2022 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 3 August 2022) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a comme...
Immunocore announces upcoming oral presentation of initial Phase 1 data of ImmTAC ® candidate IMC-F106C targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022 Oral presentation in proffered paper s...
100% technical buy signals. 13 new highs and up 38.33% in the last month. Price targets as high as $78.95. The Chart of the Day belongs to the healthcare biotech company Immunocore ( IMCR ). I found the stock by sorting Barchart's Top Stocks to Own list first by ...
Immunocore ( NASDAQ: IMCR ) agreed to sell 3.7M shares, consisting of 2M ADSs with each ADS representing one ordinary share, and 1.7M non-voting ordinary shares, to certain institutional accredited investors through a private investment in public equity financing at a pri...
P RESS RELEASE Immunocore A nnounces $ 140 Million Private Placement Financing (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 18 July 2022) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the ...
It's been an ugly year in the stock market in 2022, and most investors are deep in the red. But there's always a winner somewhere. Right now healthcare is seeing a lot of bright spots. For instance, Immunocore (NASDAQ: IMCR) investors just had a U.S. Food and Drug Administration...
P RESS RELEASE Immunocore announces dosing of first patient with ImmTAV ® bispecific for HIV IMC-M113V , T cell receptor bispecific , target s an HIV Gag antigen Single Ascending Dose portion of Phase 1 study to eval...
Baker Brothers’ 13F portfolio value decreased from $20.55B to $17.40B this quarter. Horizon Therapeutics was increased while decreasing Legend Biotech. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to almost 68% of the portfolio. ...
P RESS RELEASE Immunocore announces the presentation of initial data from the P hase 1 ImmTAV ® trial for chronic Hepatitis B at the EASL International Liver Congress™ IMC- I109V , T cell recep...
News, Short Squeeze, Breakout and More Instantly...
Immunocore Holdings plc Company Name:
IMCR Stock Symbol:
NASDAQ Market:
Immunocore Holdings plc Website:
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 73.0% to $0.4585 on volume of 640,087,036 shares Ocean Power Technologies Inc. (OPTT) rose 34.9% to $0.1812 on volume of 396,326,565 shares NVIDIA Corporation (NVDA) rose 0.2% to $1...
A look at the top 10 most actives in the United States NLS Pharmaceutics Ltd. (NLSP) rose 156.2% to $0.38 on volume of 125,047,059 shares Reliance Global Group Inc. (RELI) rose 210.8% to $0.69 on volume of 110,427,102 shares Mustang Bio Inc. (MBIO) rose 53.3% to $1.15 on volume of 87,727,...
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma The Phase 3 PRISM-MEL-301 trial will study the efficacy and safety of brenetafusp (IMC-F10...